Skip to main content

International Psoriasis Council

Advancing Knowledge. Improving Care.

Revised IPC Statement on COVID-19

REVISED IPC COVID Statement Graphic

Who is most at risk of severe COVID-19 or dying from COVID-19?

Answer: People over 60 (with risk substantially increasing in the very old) and those with underlying health issues such as obesity, diabetes, cardiovascular disease, and hematological cancer. People who have reduced or absent immunity to COVID-19, either because they are unvaccinated or because the vaccine has not been effective, are also at increased risk (compared to those who have developed immunity). Biologically, inborn errors of type I interferon pathway or having neutralizing anti-interferon autoantibodies increases the risk of severe COVID-19; however, these biomarkers are not used clinically. Psoriasis itself does not appear to be a major driver of poor COVID-19 outcomes.

What is the impact of systemic psoriasis treatments on COVID-19 outcomes?

Answer: Evidence to date suggests that most systemic therapies used for psoriasis do not meaningfully impact the risk of severe COVID-19. Prednisone, particularly when used in high doses, is associated with an increased risk of severe COVID-19 outcomes, and generally should be avoided, if possible, for the management of psoriatic disease. If prednisone is required for psoriatic arthritis, use the lowest dose needed to control symptoms.

What is the impact of psoriasis systemic treatments on the effectiveness of COVID-19 vaccines?

Answer: Treatments for psoriasis do not appear to meaningfully impact the clinical benefits of COVID-19 vaccines. This includes protection against severe COVID-19 in people with psoriasis who received vaccination while on systemic immunodulatory therapy. This observation is based primarily on data in people who received mRNA-based COVID-19 vaccines. Immunogenicity studies do, however, indicate that methotrexate, JAK inhibitors, and biologics may impact serologic (antibody) and/or cellular (T cell) responses to mRNA COVID19 vaccines. Holding methotrexate for 2 weeks after receiving an mRNA COVID19 vaccine may improve serologic (antibody level) response, although the impact on vaccine clinical effectiveness is unknown.

Who should get vaccinated for COVID-19?

Answer: The goal of COVID-19 vaccination is to reduce the risk of severe COVID-19, including hospitalization and death. Many different COVID-19 vaccines are now licensed, are highly effective in preventing severe COVID-19, and have prevented millions of COVID-19 deaths worldwide. In general, people living with psoriasis should get a primary vaccination regimen against COVID-19. Protection from severe COVID-19 outcomes may reduce somewhat over time. Booster vaccines to maintain immunity may be necessary, especially in those who received primary vaccination while on immunomodulating therapies and / or those at high risk for severe COVID-19 outcomes. Serious side effects from COVID-19 vaccines are very rare (<1 in every 10,000 people). There have been some reports of new onset or exacerbation of psoriasis and/or psoriatic arthritis in people receiving COVID-19 vaccines; however, these reports are uncommon, and a causal relationship has not been established.

Who should receive specific treatment for COVID-19 in the outpatient setting?

Answer: Several antiviral drugs are licensed for patients with mild-moderate COVID-19 at high risk of progressing to severe disease in many countries. Treatment for COVID-19 needs to be administered within days of the onset of symptoms to be effective. Drug choice, depending on patients’ immune status and underlying comorbidities or treatments, and prioritization of treatments vary by region and may change over time.

This statement is based on expert opinion and should be interpreted in the context of local policies and emerging evidence.
[thrive_leads id='12019']

Categories

Recent Posts

FDA Labeling Now Aligns with the IPC and NPF Joint Position Statement on Tuberculosis Testing

Dose Reduction of IL-17 and IL-23 Inhibitors: Are We Ready for Tailored Dosing in the Era of Disease Modification?

Remembering Dr. Craig Leonardi

Also Read

Craig Leonardi

Remembering Dr. Craig Leonardi

The International Psoriasis Council (IPC) remembers Dr. Craig Leonardi, founding member and former President, whose research shaped modern psoriasis treatment.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

What's New

Remembering Dr. Craig Leonardi

The International Psoriasis Council (IPC) remembers Dr. Craig Leonardi, founding member and former President, whose research shaped modern psoriasis treatment.

Read More »

Look Beyond My Skin: World Psoriasis Day 2026

World Psoriasis Day, observed each year on October 29, was launched by the International Federation of Psoriasis Associations (IFPA) in 2004 to give a voice to the more than 125 million people worldwide living with psoriasis and psoriatic arthritis. To mark this year’s observance, IPC joined the Latin American Society of Psoriasis and Dermoimmunology (SOLAPSO) and the Skin Inflammation and Psoriasis International Network (SPIN) to create a video series around the theme “Look Beyond My Skin,” featuring voices from all three organizations. Missed the videos on social media? Watch the full series on the IPC YouTube channel.

WATCH NOW

Thursday, October 29, 2026

Introducing Take Two with IPC: Expert Talks in Two Minutes

Take Two with IPC gives a longer presentation a second life in two minutes. Each video takes an expert talk IPC has already published (a Take Ten recording or a symposium presentation) and condenses the clinical substance. The series launched this month alongside the World Psoriasis Day campaign with four videos on pediatric psoriasis: Psoriasis Look-Alikes and Anti-TNF-α Induced Skin Eruptions with IPC Board Member Amy Paller, MS, MD; Conventional Therapies with IPC Councilor Mona El-Kalioby, MBBCh, MSc, MD; and Phototherapy in Pediatric Psoriasis with Fernando Valenzuela, MD. New Take Two videos will be featured each month, drawn from the Take Ten with IPC library and recordings from IPC symposia, with a link to the full presentation for each.

WATCH NOW

Thursday, October 29, 2026

Videos Now Available from the Eczema and Psoriasis Research Incubator

Select presentations from the Eczema and Psoriasis Research Incubator: Cross-Disciplinary Innovation Forum, hosted by the International Eczema Council (IEC) and International Psoriasis Council (IPC) at the 55th Annual European Society for Dermatological Research (ESDR) Meeting, are now available. Topics include disease endotypes, atopic dermatitis-psoriasis overlap, cardiovascular risk in psoriasis, and genetic susceptibility.

WATCH NOW

Monday, October 26, 2026

Sex Differences in Psoriasis

In this Take Ten with IPC video, Juul van den Reek and PhD candidate Liana Barenbrug discuss sex differences in psoriasis, why these distinctions matter, what current research tells us, and which areas should be prioritized in future psoriasis research.

WATCH NOW

Thursday, October 1, 2026